Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$4.49 -2.1%	$3.93	$1.89 ▼ $5.82	$1.34B	0.65	5.09 million shs	5.50 million shs
CDTX Cidara Therapeutics	$63.44 +0.3%	$48.12	$10.14 ▼ $66.94	$1.61B	1.18	372,845 shs	539,211 shs
RCKT Rocket Pharmaceuticals	$3.04 -1.8%	$2.95	$2.19 ▼ $22.01	$327.48M	0.65	3.34 million shs	1.14 million shs
VERA Vera Therapeutics	$21.33 -2.9%	$22.34	$18.53 ▼ $51.61	$1.36B	1.17	1.30 million shs	1.48 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	+7.17%	+11.07%	+7.92%	+126.53%	+71.39%
CDTX Cidara Therapeutics	+2.02%	+2.03%	+14.33%	+200.62%	+420.58%
RCKT Rocket Pharmaceuticals	+6.19%	+2.32%	+1.31%	-54.02%	-83.85%
VERA Vera Therapeutics	+3.93%	+14.13%	-7.61%	+3.00%	-42.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCL AbCellera Biologics	3.2497 of 5 stars	4.5	1.0	0.0	2.9	3.3	0.0
CDTX Cidara Therapeutics	3.7361 of 5 stars	2.6	3.0	4.6	3.2	1.7	0.0
RCKT Rocket Pharmaceuticals	4.8701 of 5 stars	4.2	4.0	4.7	1.7	4.2	1.3
VERA Vera Therapeutics	3.4269 of 5 stars	4.5	3.0	0.0	1.0	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	3.00	Buy	$8.00	78.37% Upside
CDTX Cidara Therapeutics	3.11	Buy	$64.14	1.11% Upside
RCKT Rocket Pharmaceuticals	2.35	Hold	$16.33	438.17% Upside
VERA Vera Therapeutics	2.90	Moderate Buy	$63.00	195.43% Upside

Current Analyst Ratings Breakdown

Latest RCKT, VERA, ABCL, and CDTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
8/8/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	ABCL AbCellera Biologics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
8/8/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$59.00 ➝ $66.00
8/8/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $74.00
8/8/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $74.00
8/8/2025	RCKT Rocket Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $8.00
8/7/2025	VERA Vera Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$56.00 ➝ $53.00
8/4/2025	VERA Vera Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Peer Perform
7/25/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
7/25/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$9.00 ➝ $4.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$28.83M	46.49	N/A	N/A	$3.37 per share	1.33
CDTX Cidara Therapeutics	$1.27M	1,266.72	N/A	N/A	$19.76 per share	3.21
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$3.28 per share	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	$7.34 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$162.86M	-$0.55	N/A	N/A	N/A	-511.88%	-16.17%	-12.24%	N/A
CDTX Cidara Therapeutics	-$169.83M	-$11.13	N/A	N/A	N/A	N/A	-50.81%	-42.46%	N/A
RCKT Rocket Pharmaceuticals	-$258.75M	-$2.51	N/A	N/A	N/A	N/A	-65.11%	-55.99%	N/A
VERA Vera Therapeutics	-$152.15M	-$3.58	N/A	N/A	N/A	N/A	-46.70%	-39.46%	N/A

Latest RCKT, VERA, ABCL, and CDTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	VERA Vera Therapeutics	-$0.82	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	ABCL AbCellera Biologics	-$0.17	-$0.12	+$0.05	-$0.12	$7.55 million	$17.08 million
8/7/2025	Q2 2025	CDTX Cidara Therapeutics	-$1.87	-$1.65	+$0.22	-$1.65	N/A	N/A
8/7/2025	Q2 2025	RCKT Rocket Pharmaceuticals	-$0.57	-$0.59	-$0.02	-$0.62	$4.36 million	N/A
8/5/2025	Q2 2025	VERA Vera Therapeutics	-$0.82	-$1.20	-$0.38	-$1.20	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	11.07	11.07
CDTX Cidara Therapeutics	N/A	16.45	3.87
RCKT Rocket Pharmaceuticals	0.05	6.39	9.19
VERA Vera Therapeutics	0.16	17.03	17.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
CDTX Cidara Therapeutics	35.82%
RCKT Rocket Pharmaceuticals	98.39%
VERA Vera Therapeutics	99.21%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.90%
CDTX Cidara Therapeutics	3.89%
RCKT Rocket Pharmaceuticals	24.76%
VERA Vera Therapeutics	16.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	298.83 million	212.47 million	Optionable
CDTX Cidara Therapeutics	90	25.36 million	24.37 million	No Data
RCKT Rocket Pharmaceuticals	240	107.90 million	81.19 million	Optionable
VERA Vera Therapeutics	40	63.77 million	53.38 million	Optionable

RCKT, VERA, ABCL, and CDTX Headlines

Recent News About These Companies

Vera Therapeutics, Inc. (NASDAQ:VERA) Receives $63.00 Average Price Target from Analysts

August 12 at 2:31 AM | americanbankingnews.com

JPMorgan Chase & Co. Cuts Vera Therapeutics (NASDAQ:VERA) Price Target to $53.00

August 10, 2025 | americanbankingnews.com

Cantor Fitzgerald Analysts Lower Earnings Estimates for VERA

August 10, 2025 | americanbankingnews.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Moderate Buy" by Analysts

August 10, 2025 | marketbeat.com

Lifesci Capital Issues Negative Forecast for VERA Earnings

August 10, 2025 | americanbankingnews.com

FY2025 EPS Estimates for VERA Cut by Cantor Fitzgerald

August 9, 2025 | marketbeat.com

HC Wainwright Has Negative Estimate for VERA Q3 Earnings

August 9, 2025 | marketbeat.com

What is Lifesci Capital's Forecast for VERA Q3 Earnings?

August 9, 2025 | marketbeat.com

HC Wainwright Analysts Lower Earnings Estimates for VERA

August 9, 2025 | americanbankingnews.com

JPMorgan Chase & Co. Issues Pessimistic Forecast for Vera Therapeutics (NASDAQ:VERA) Stock Price

August 8, 2025 | marketbeat.com

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 8, 2025 | globenewswire.com

Vera Therapeutics Signs New Sales Agreement with TD Securities

August 8, 2025 | theglobeandmail.com

Q3 Earnings Forecast for Vera Therapeutics Issued By Wedbush

August 8, 2025 | marketbeat.com

Vera Therapeutics (VERA) to Release Quarterly Earnings on Thursday

August 7, 2025 | marketbeat.com

Vera Therapeutics (NASDAQ:VERA) Posts Earnings Results, Misses Estimates By $0.38 EPS

August 6, 2025 | marketbeat.com

Vera (VERA) Q2 Net Loss Widens 127%

August 6, 2025 | fool.com

Vera Therapeutics (NASDAQ:VERA) Shares Gap Down - What's Next?

August 5, 2025 | marketbeat.com

Wolfe Research Downgrades Vera Therapeutics (VERA)

August 5, 2025 | msn.com

Vera Therapeutics' (VERA) "Peer Perform" Rating Reaffirmed at Wolfe Research

August 5, 2025 | marketbeat.com

Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

August 5, 2025 | globenewswire.com

Vera Therapeutics' (VERA) "Peer Perform" Rating Reiterated at Wolfe Research

August 5, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RCKT, VERA, ABCL, and CDTX Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$4.49 -0.10 (-2.07%)

Closing price 03:59 PM Eastern

Extended Trading

$4.56 +0.07 (+1.56%)

As of 04:11 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Cidara Therapeutics NASDAQ:CDTX

$63.44 +0.19 (+0.29%)

Closing price 03:59 PM Eastern

Extended Trading

$63.48 +0.05 (+0.08%)

As of 04:10 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.04 -0.06 (-1.78%)

Closing price 03:59 PM Eastern

Extended Trading

$3.04 0.00 (0.00%)

As of 04:10 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Vera Therapeutics NASDAQ:VERA

$21.32 -0.65 (-2.94%)

Closing price 03:59 PM Eastern

Extended Trading

$21.26 -0.06 (-0.30%)

As of 04:10 PM Eastern

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time